Mass spectrometry-based antigen discovery for cancer immunotherapy

摘要: The antigenic landscape of tumors is distinct from healthy cells and has been the rationale behind a variety vaccination trials. Typically target tumor-associated antigens have self origin rarely induced effective anti-tumor responses. Recent data show that activation immune system by checkpoint blocking therapies leads to tumor rejection recognition mutated antigens, known as 'neo-antigens' plays key role. Discovery neo-antigens relies mainly on prediction-based interrogation 'mutanome' using genomic information input, followed T-cell screening. breakthroughs in mass spectrometry (MS) based immunopeptidomics allowed discovery very large pools naturally presented peptides, among them neo-epitopes. This review highlights current progress related with emphasis prediction algorithms MS well synergy two methodologies how they can be exploited develop personalized immunotherapy.